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HIV  prevalence  worldwide  among  people  who  inject  drugs  (PWID)  is  around  19%. Harm  reduction  for
PWID includes  needle-syringe  programs  (NSPs)  and  opioid  substitution  therapy  (OST)  but  often  coupled
with antiretroviral  therapy  (ART)  for  people  living  with  HIV.  Numerous  studies  have  examined  the  effec-
tiveness  of each  harm  reduction  strategy.  This  commentary  discusses  the  evidence  of effectiveness  of
the packages  of  harm  reduction  services  and  their  cost-effectiveness  with  respect  to  HIV-related  out-
comes  as  well  as estimate  resources  required  to meet  global  and  regional  coverage  targets.  NSPs  have
been  shown  to be  safe  and  very  effective  in  reducing  HIV  transmission  in diverse  settings;  there  are
many  historical  and  very  recent  examples  in  diverse  settings  where  the  absence  of, or reduction  in,  NSPs
have  resulted  in exploding  HIV epidemics  compared  to  controlled  epidemics  with  NSP  implementation.
NSPs  are  relatively  inexpensive  to implement  and  highly  cost-effective  according  to commonly  used
willingness-to-pay  thresholds.  There  is  strong  evidence  that substitution  therapy  is  effective,  reducing
the  risk  of HIV  acquisition  by  54% on average  among  PWID.  OST  is  relatively  expensive  to implement  when
only HIV outcomes  are  considered;  other societal  beneﬁts  substantially  improve  the  cost-effectiveness
ratios  to be  highly  favourable.  Many  studies  have  shown  that ART  is cost-effective  for keeping  people
alive  but  there  is only  weak  supportive,  but growing  evidence,  of  the  additional  effectiveness  and  cost-
effectiveness  of  ART as prevention  among  PWID.  Packages  of combined  harm  reduction  approaches  are
highly  likely  to be  more  effective  and  cost-effective  than  partial  approaches.  The  coverage  of  harm  reduc-
tion programs  remains  extremely  low  across  the  world.  The  total  annual  costs  of  scaling  up each  of  the
harm  reduction  strategies  from  current  coverage  levels,  by  region,  to meet  WHO  guideline  coverage  tar-
gets are  high  with  ART  greatest,  followed  by  OST  and  then  NSPs.  But  scale-up  of  all  three  approaches  is
essential.  These  interventions  can  be cost-effective  by  most  thresholds  in the short-term  and  cost-saving
in  the  long-term.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-NDntroduction
HIV prevalence worldwide among people who inject drugs
PWID) is around 19% (World Health Organization, 2013) and
lmost one-third of HIV incident cases outside sub-Saharan Africa
re related to injecting drug use (Open Society Institute, 2004).
njecting drug use is estimated to be responsible for around 10%
f all HIV infections worldwide (UNAIDS, 2012). The spread of HIV
mong PWID has particularly driven epidemics throughout regions
f Eastern Europe, and Central and Southeast Asia (Bridge, Lazarus,
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955-3959/© 2015 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
& Atun, 2010; El-Bassel et al., 2014; Wu,  Shi, & Detels, 2013). Indeed,
in Eastern Europe and Central Asia the majority of HIV infections
have been attributed to injecting drug use and this is the region
of the world currently with the largest increase in HIV epidemics
(UNAIDS, 2012). Some countries in the Middle East and North
Africa region have also been experiencing rapidly emerging HIV
epidemics among PWID (Mumtaz et al., 2014).
Many countries in Asia and Eastern Europe have responded to
injecting drug use through law enforcement measures and com-
pulsory detention (Wu,  2013). There is no evidence to suggest that
compulsory detention of people who use drugs is effective in reduc-
ing drug dependency or rehabilitative, as most detained people
return to drug dependency after release (Hall et al., 2012; WHO,
2009a). An alternate approach is harm reduction, which refers to
methods of reducing health risks when eliminating them may  not
be possible. Harm reduction can also reduce social and economic
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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arms that individuals experience as a result of engaging in risky
ctivities. In the context of HIV prevention and injecting drug use,
arm reduction generally includes needle-syringe programs and
pioid substitution therapy. Provision of antiretroviral therapy is
lso considered to be within a comprehensive package of HIV-
elated services for PWID. Harm reduction approaches were ﬁrst
ntroduced in the Netherlands, United Kingdom and Australia in the
id-1980s in response to AIDS epidemics (Stimson, 1989). We  now
ave three decades of data to assess the evidence of effectiveness
nd cost-effectiveness of these approaches. In this commentary,
e discuss the cost-effectiveness of harm reduction with respect
o HIV-related outcomes. We  refer the reader to a complemen-
ary commentary in this issue by Bruggman and Grebely which
ddresses harm reduction and hepatitis C virus (HCV) epidemics,
ncluding the large opportunity to incorporate new paradigm-
hifting HCV treatments into harm reduction packages (Bruggmann
 Grebely, 2015).
Although they do not necessarily reduce drug dependency,
eedle-syringe programs (NSPs) are public health measures which
im to reduce the spread of blood-borne infections, including HIV
nd HCV, among PWID through the distribution of sterile inject-
ng equipment. NSPs operate in many different modes in different
ontexts and they may  provide a range of services that include
he provision of injecting equipment, education and information
n reduction of drug-related harms, referral to drug treatment,
edical care and legal and social services (Heimer, 1998; Kidorf
 King, 2008). Another harm reduction strategy, opioid substi-
ution therapy (OST), has a dualistic aim of ﬁrstly reducing drug
ependency among PWID, but secondly and subsequently reduc-
ng the frequency of injection and unsafe injecting practices which
hereby reduces blood-borne viral transmission via injecting drug
se. Methadone or other opioid substitutes are prescribed to depen-
ent users to diminish the use and effects of opiates. The provision
f ART has also become an ethically-sound and pragmatic inter-
ention for PWID who are also living with HIV, as it reverses
isease progression to increase the length and quality of life (Lohse
t al., 2007). ART also reduces viral load which is expected to also
ecrease the likelihood of onward HIV transmission (Cohen et al.,
011; Wilson et al., 2008). These three harm reduction strategies
lso comprise the main elements of a nine-component comprehen-
ive package, endorsed by the WHO, UNODC and UNAIDS (WHO,
009b).
Numerous studies have examined the effectiveness of each
arm reduction strategy. Each approach has clear evidence of
mpact on reducing drug dependency or reducing risk behaviours
nd ultimately averting HIV transmission (among other important
eneﬁts). A recent systematic review of HIV prevention programs
hrough Asia and Eastern Europe found that interventions tar-
eted at speciﬁc population groups, including harm reduction
rograms for PWID, demonstrated evidence of effectiveness and
ost-effectiveness when compared to non-targeted other HIV inter-
entions aimed at the general populations (Craig, 2014). This
ommentary assesses NSPs, OST and ART in isolation and then
roadly the evidence of them in combination. The amount of money
hich society, governments and other funders are willing to pay for
ealth and societal beneﬁts is substantially different between set-
ings, interventions and populations. We  do not deﬁne a speciﬁc
illingness-to-pay threshold for harm reduction; rather, we com-
ent on general conclusions from studies on the cost-effectiveness
atios calculated.
ffectiveness and cost-effectiveness of NSPsNSPs have been shown to be safe and effective in reducing
IV transmission in diverse settings (Bastos & Strathdee, 2000;
enkins et al., 2001; Kwon et al., 2009; Vickerman et al., 2006; of Drug Policy 26 (2015) S5–S11
Wodak, 2006). A recent review of reviews found sufﬁcient evi-
dence of NSPs to reduce self-reported risky injecting behavior
and tentative evidence of effectiveness of NSPs to reduce HIV
transmission (Palmateer et al., 2010). Two  recent comprehensive
reviews found compelling evidence that NSPs are associated with
favorable outcomes for PWID (Gibson, Flynn, & Perales, 2001;
Wodak & Cooney, 2005) with the more recent review ﬁnding that
increasing the availability of sterile injecting equipment to PWID
reduces HIV infection; 23 of 33 studies reviewed found positive
outcomes on HIV risk behavior, with one ﬁnding negative out-
comes, 5 having indeterminate outcomes, and 6 investigating a
variety of other outcomes with either positive or indeterminate
results (Wodak & Cooney, 2005). Further, a review of ecologi-
cal data from 81 cities across Europe, Asia and North America
found that HIV prevalence increased by an average of 5.9% per
year in the 52 cities without NSPs but HIV prevalence decreased
by 5.8% per year in the 29 cities with NSPs (Hurley, Jolley, &
Kaldor, 1997); note that mortality rates at the time of this study
may  have inﬂuenced prevalence trends. A particularly notable
example of impact was demonstrated in New York, where the
introduction of NSPs was associated with a sharp decrease of
HIV incidence in the early 1990s from 4% per year to 1% (Des
Jarlais et al., 1996, 2005). There are many examples where the
lack of NSPs has led to large increases in HIV incidence. For
example, HIV prevalence in Cebu, Philippines recently escalated
drastically from 0.5% in 2009 to 53% in 2011; similarly rapidly
exploding epidemics have been observed in Sargodha (Pakistan),
Bangkok (Thailand) and Manipur (India) where HIV prevalence
increased from near zero within a few months to reach levels of
20–50% (Choopanya et al., 1991; Emmanuel et al., 2009; Sarkar
et al., 1993). NSPs reduce the probability of transmission of HIV
and other blood-borne diseases by lowering the rates of shar-
ing of injecting equipment among PWID. Surveillance in Victoria
and Vancouver, Canada found that there were similar behaviors
in the two cities with NSPs but subsequent to the closure of
needle-exchange clinics in Victoria, needle sharing became signif-
icantly more prevalent (23%) in Victoria compared to Vancouver
(8%) where needle exchange clinics remained open (Ivsins et al.,
2010).
NSPs are relatively inexpensive to implement. The average cost
of NSP provision has been estimated by UNAIDS to be US$23–71
per person per year (Wilson & Nicole, 2013) depending on region of
the world and delivery system (pharmacies, specialist programme
sites, vending machines, mobile outreach vehicles) (Schwartlander
et al., 2011). Given their relatively low costs and evidence of effec-
tiveness, NSPs are recognized as one of the most cost-effective
public health interventions ever funded (International, 2012). Stud-
ies in numerous countries have repeatedly provided compelling
evidence that NSPs are cost-effective both from societal and health
sector perspectives (Vickerman, Miners, & Williams, 2008; Wodak
& Maher, 2010). A systematic review found that all 12 included
studies that examined the impact of NSPs on HIV infection found
that NSPs were cost-effective according to the studies’ deﬁned
willingness-to-pay thresholds (Jones, Pickering, Sumnall, McVeigh,
& Bellis, 2008). Increasingly, evidence has found net ﬁnancial bene-
ﬁts of NSPs across all regions and in high- and low-income settings
(Belani Hrishikesh & Muennig, 2008; Guinness et al., 2010; Ni et al.,
2012). For example, NSPs are cost saving when compared to the life-
time costs of HIV/AIDS antiretroviral treatment (Jones et al., 2008)
and a recent study estimated that not only did NSPs reduce the
incidence of HIV by up to 74% over a 10 year period in Australia
but found that they were cost savings and had a return on invest-
ment of between $1.3 and $5.5 for every $1 invested (Kwon et al.,
2012). Table 1 illustrates the cost-effectiveness ratios of NSPs in
Eastern Europe and Central Asia where injecting drug use is preva-
lent.
D.P. Wilson et al. / International Journal
Table  1
Illustrative examples of cost-effectiveness of NSP in Eastern Europe and Central Asia
(implemented 2000–2010).
Country QALYs gained ICER (US $ per QALY gained)
Armenia 223–251 Return ∼ investment
Belarus 1310–1642 $1405–1896
Estonia 41–53 $102,375–132,374
Georgia 41–56 $19,811–27,633
Kazakhstan 2364–2518 $5758–6256
Moldova 559–1026 $1882–3640
Tajikistan 909–1283 $2104–3024
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ource: Wilson et al. (2014).
ffectiveness and cost-effectiveness of OST
There is evidence that substitution therapy for heroin and other
piates is effective in reducing drug use and behavior related to
ransmission of blood-borne viruses, including complete cessation
f injecting drug use (Ball et al., 1988; Hubbard et al., 1988; OECD
t al., 2014; Yancovitz et al., 1991). A recent meta-analysis of stud-
es conducted in North America, Europe and Asia found that OST
sing methadone maintenance treatment was  associated with a
4% reduction in risk of having HIV infection among PWID (rate
atio of 0.46, 0.32–0.67 95%CI) (MacArthur et al., 2012). Numerous
ochrane reviews have been conducted on OST with respect to their
ffectiveness in treating opioid dependence, psychosocial and other
utcomes; one of these reviews addressed the evidence of OST for
revention of HIV infection (Gowing et al., 2011). It found that OST
educes drug-related behaviours with a high risk of HIV transmis-
ion, but has less effect on sex-related risk behaviours, and that the
ack of data from randomised controlled studies limits the strength
f the evidence. It is unethical to design a randomised controlled
tudy and thus difﬁcult to obtain stronger evidence than exists on
he effectiveness of OST.
OST is more expensive than NSPs at US$363–1057 per patient
er year for 80 mg  methadone and US$1236–3167 per patient
er year for buprenorphine (Schwartlander et al., 2011). Despite
he higher costs, modelling studies have estimated that OST is a
arginally-to-reasonably cost-effective strategy when compared
o current practice and considering HIV beneﬁts only (Degenhardt
t al., 2010), ranging from a cost of US$3324 per HIV infection
verted (as indicated by a study in Vietnam) (Tran et al., 2012)
o approximately US$7000 per HIV infection averted (as demon-
trated by a study of HIV prevention in a high prevalence Indonesian
etting) (Wammes  et al., 2012). However, the largest beneﬁts of
ST are related to wider psychosocial and social beneﬁts includ-
ng reduction in the number and severity of relapses due to opiate
se, and reduced rates of criminal activity and incarceration for
rug-related crimes. If these factors are also included in economic
nalyses, OST is substantially more cost-effective. Furthermore,
ST has wider quality of life and economic beneﬁts (Hammett,
014). For example, a recent study found that methadone main-
enance therapy is associated with large reductions in health care
ervice utilization, reduced out-of-pocket costs by HIV-positive
eople who use drugs and could likely reduce the economic vulner-
bility of households affected by injecting drug use (TRan & Nguyen,
013).
In terms of comprehensive HIV responses, OST programs fall
nto the category of structural interventions, which addresses mul-
isectoral, distal drivers of HIV infection. In implementing these
nterventions as part of a repertoire of HIV interventions, the pol-
cy environment recognizes the reality that these types of programs
ave multiple health-related and other beneﬁts. Such structural
IV interventions call for cross-sector ﬁnancing models, which dis-
ribute the costs in accordance with the beneﬁts (Remme  et al., of Drug Policy 26 (2015) S5–S11 S7
2012). If a cross-sector cost-beneﬁt analysis is applied to cost-
effectiveness analyses of OST (e.g., by replicating the method used
by Remme  et al. when examining structural interventions such as
cash transfers to young women (Remme  et al., 2012, 2014)) then the
overall cost-effectiveness ratios of OST would improve by a factor
of around 10–20-fold (results not shown). OST is thus highly cost-
effective according to almost any willingness-to-pay thresholds.
Effectiveness and cost-effectiveness of ART
There is strong evidence, including from a randomised con-
trolled trial, that ART reduces infectivity among HIV-positive
heterosexuals (Anglemyer et al., 2011; Attia et al., 2009; Cohen
et al., 2011; Quinn et al., 2000). Currently, there is little evidence
that treatment as prevention is as effective for MSM  and for PWID
although it is highly plausible that this strategy is likely to reduce
transmission rates substantially among these groups (Kelley et al.,
2011; Wilson, 2010). Additionally, ART may  also be given to HIV-
negative individuals as pre-exposure prophylaxis (PrEP). PrEP has
now been shown to reduce transmission among PWID by 48.9% in
the Bangkok Tenofovir Study (BTS) (Choopanya et al., 2013); how-
ever, we  note that this trial was  undertaken in an environment
where other harm reduction approaches are highly restricted and
illegal.
While UNAIDS estimated that the minimum cost of providing
ART to be US$176 per person per year in 2010 and project this cost
to decline to USD $125 by 2020, studies have indicated that the
average annual costs of treating an HIV-positive PWID per year can
be anywhere between US$1000 and US$2000 in low- and middle-
income countries (Wilson & Nicole, 2013).
Many studies have shown that ART is cost-effective not only for
the purpose of keeping people alive but also because of its preven-
tion beneﬁts (Kahn et al., 2011; Loubiere et al., 2010; Wilson et al.,
2014). Considering the prevention and treatment beneﬁts, ART is
a highly favourable intervention. However, there is relatively little
evidence of cost-effectiveness of ART speciﬁcally targeted to PWID.
A study in Russia estimated that ART would cost around US$1501
per QALY gained when targeted to PWID which is considered good
value for money (Long et al., 2006). The cost-effectiveness of PrEP
for PWID will vary according to HIV incidence among the PWID
targeted and with the cost of PrEP. Assuming that the measured efﬁ-
cacy of PrEP among PWID in the BTS (of 48.9%) is maintained with
broader scale-up outside of a trial setting, cost-effectiveness ratios
can be estimated. In high-income countries, the cost per HIV infec-
tion averted would range between US$25,000–1.8 million; the cost
per infection averted would be US$4200–75,000 when discounted
tenofovir is available and US$1200–18,000 where generic teno-
fovir is available (Craig et al., 2013). These ranges suggest that PrEP
may  not be cost-effective in all settings compared with commonly
funded health interventions.
It is important to note that coverage of ART among HIV-positive
PWID is less than 1% in many countries (Mathers et al., 2010). It
would be expected that coverage of antiretrovirals among HIV-
negative PWID would be substantially lower. Therefore, due to
expected low coverage and unimpressive cost-effectiveness ratios,
we believe that PrEP is unlikely to be largely utilised for HIV preven-
tion among PWID. However, ART for people living with HIV would
be very cost-effective.
Effectiveness and cost-effectiveness of combination strategies
No single harm reduction approach is sufﬁcient. The evidence
suggests that comprehensive prevention strategies are synergis-
tic (Beyrer et al., 2010; Lert & Kazatchkine, 2007; Strathdee et al.,
2012; Wood et al., 2002). Modelling for Eastern Europe and Cen-
tral Asia has shown that NSPs alone have small effect unless they
S8 D.P. Wilson et al. / International Journal of Drug Policy 26 (2015) S5–S11
Table 2
Estimated annual cost of scaling up harm reduction by region.
Region Harm reduction strategy
(current coverage)a
Annual cost (USD) of scale up to reach ‘Mid
coverage targets’ (%)b
Annual cost (USD) of scale up to reach High
coverage targets (%)b
South East Asia NSP (11.5%) $26,844,300 (20% Coverage) $153,600,300 (60% coverage)
OST (5.9%) $360,975,675 (20% Coverage) $872,526,675 (40% Coverage)
ART  (3.6%) $856,463,175 (25% Coverage) $2,859,660,675 (75% Coverage)
Eastern  Europe and Central
Asia
NSP (11.7%) $19,099,100 (20% Coverage) $111,454,300 (60% coverage)
OST  (<1%%) $715,465,800 (20% Coverage) $1,466,224,200 (40% Coverage)
ART  (1.1%) $1,163,126,925 (25% Coverage) $3,593,036,925 (75% Coverage)
Latin  America and the
Caribbean
NSP (2%) $8,331,120 (20% Coverage) $26,844,720 (60% coverage)
OST  (<1%) $427,631,100 (20% Coverage) $857,411,100 (40% Coverage)
ART (1%) $690,292,800 (25% Coverage) $2,128,402,800 (75% Coverage)
Middle East and North Africa NSP (2.0%) $1,350,360 (20% Coverage) $4,351,160 (60% coverage)
OST  (1%) $23,173,920 (20% Coverage) $47,567,520 (40% Coverage)
ART  (<1%) $34,091,750 (25% Coverage) $102,275,250 (75% Coverage)
Western Europe, North
America and Australasia
NSP (17.0%) $16,625,550 $238,299,550
OST (27.8%) – $954,741,990
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a Source: Mathers et al. (2010).
b Source: Scale-up calculations by UNSW.
re combined with other evidence-informed, rights-based combi-
ation interventions, particularly access to OST and ART (Lacombe
 Rockstroh, 2012). Programs which employ a combination of harm
eduction strategies have had demonstrable success in improving
ealth outcomes for PWID (Degenhardt et al., 2010). Such a strat-
gy in Amsterdam resulted in a 57% decrease in HIV incidence and
4% decrease in HCV incidence in a distinct cohort (Van Den Berg
t al., 2007). Similar positive results have been found in Malaysia,
here a combination of harm reduction programs have averted an
stimated 12,653 HIV infections since 2006 (Naning et al., 2013).
urthermore, adherence to ART could likely be improved if com-
ined with OST programs (WHO, 2012).
Combination programs that combine harm reduction interven-
ions have also demonstrated good value for money (Degenhardt
t al., 2010). This includes a recent study in Ukraine which found
hat a harm reduction strategy which expands both methadone and
RT to PWID is not only more effective than a methadone-only
trategy, but is also deemed to be cost-effective at an estimated
S$1120/QALY gained (Alistar, Owens, & Brandeau, 2011). Another
tudy in China found the expansion of combination strategies
hich employ ART, voluntary testing and counselling, and harm
eduction to cost an estimated $9310 per QALY gained when com-
ared to a base case of essentially no harm reduction program (Li
t al., 2012); this is likely to be around or less than willingness-to-
ay thresholds for upper-middle-income countries like China.
caling up harm reduction interventions and evidence of returns
n investment
Despite increasing prevalence of injecting drug use and
stablished evidence of effectiveness and cost-effectiveness, the
overage of harm reduction programs remains appallingly low
Mathers et al., 2010).
As of 2012, there were 97 countries and territories that sup-
orted a harm reduction approach, exempliﬁed either in national
olicy documents or tolerance or implementation of harm reduc-
ion interventions (International, 2012). Yet, high coverage (deﬁned
y the 2009 WHO, UNAIDS, UNODC Technical Guide as more than
00 needles or syringes provided per PWID per year) of NSPs has
nly been achieved in a few countries in Europe, Australia, a small
umber of countries in Asia, Brazil, and Iran (UNAIDS, 2013; Des
arlais et al., 2013). A recent review suggested that only 10% of PWID
n Eastern Europe and 36% in Central Asia access NSPs, with an aver-
ge of nine and 92 needle-syringes distributed per PWID per year,–
respectively (Mathers et al., 2010). As such, an estimated 90% of
PWID worldwide are not accessing NSPs. Despite being provided
in 77 countries worldwide, there are also signiﬁcant coverage gaps
with OST, which remains unavailable in 81 countries with reported
injecting drug use. Furthermore, it is estimated that only 8% of PWID
globally have access to OST, with coverage particularly low in parts
of sub-Saharan Africa, Latin America and Asia. Encouragingly how-
ever, high OST coverage has been reported in Iran, Czech Republic
and Western Europe, and several countries in Asia and the Mid-
dle East have begun to scale-up their programs; China has recently
had the largest OST scale-up program in the world. Uptake of ART
by HIV-infected PWID shows the largest disparities with what is
required or deemed to be appropriate access. Only 14% of HIV-
positive PWID globally have access to ART, with the largest gaps
in ART provision in Eastern Europe and Central Asia (where almost
no PWID in some countries have access to ART).
It is clear that harm reduction programs have yet to be scaled
up or implemented in a way  to be commensurate with their
expected population beneﬁts and yield the full economic beneﬁts
(International, 2012). Even where new initiatives have been imple-
mented, they are generally small-scale (International, 2012). More
worryingly, numerous countries with some of the highest HIV bur-
dens among PWID have appeared to signiﬁcantly scale down harm
reduction interventions (International, 2012). This is likely due to
previous support from international donors being withdrawn and
not replaced by domestic sources.
There are numerous socio-political and legislative reasons for
poor coverage of harm reduction. Coverage cannot be improved
without ﬁrst addressing the stigma, discrimination and intolerance
that restricts the expansion of harm reduction. Addressing these
barriers remains of paramount importance for facilitating effective
harm reduction programs. We  refer the reader to a complementary
commentary in this issue by Strathdee et al. on harm reduction and
the law (Strathdee et al., 2015).
The evidence presented here suggests that all harm reduction
interventions could be further expanded. The potential reach and
costs of scaling up any of the three interventions are dependent not
only of the costs of the intervention, but also on the prevalence of
injecting drug use and on the current coverage of interventions. In
Table 2 we provide our estimates of the total annual costs of scal-
ing up each of the harm reduction strategies from current coverage
levels, by region, to meet WHO  guideline coverage targets. We  note
that required costs for ART are greater than for NSPs and OST. How-
ever, ART budgets should be separate to harm reduction budgets. In
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very region of the world, coverage of NSPs is substantially greater
han coverage of OST. OST is more expensive than NSPs and there-
ore it is not surprising that it will cost a lot more to scale up OST
o mid-levels than it would take to scale-up NSPs to high levels.
t would be relatively inexpensive to attain mid-coverage levels of
SPs across every region of the world.
Scale up of all three approaches is essential. These interven-
ions can be cost-effective in the short-term according to common
ocally applied willingness-to-pay thresholds and cost-saving in the
ong-term. There are economies of scale as programs mature and
ncrease in coverage (Marseille et al., 2007; Menzies et al., 2011).
ncreasing coverage may  require governments to expand national
ublic sector infrastructure, health systems capacity, and outreach
ervices whereas achieving requisite scale efﬁciency could entail
ncreasing delivery systems with low ﬁxed operation costs, through
rop-in centers and other innovative approaches (Lurie et al., 1998).
n particular, reductions in unit costs can further improve the cost-
ffectiveness of these approaches, in particular when these are
mplemented in an overall comprehensive and evidence-informed
anner (Tilson & Bozzette, 2007).
onclusion
The need to improve health outcomes for PWID, including
educing the high and increasing rates of HIV (and HCV) transmis-
ion, remains an urgent task for health providers and governments
cross the world. The coverage of harm reduction programs among
WID populations is currently too low across almost all global
egions and the programs have yet to sufﬁciently scale up to lead to
he population impact commensurate with their known effective-
ess and cost-effectiveness. Not only is there an ethical imperative
o make harm reduction programs universally available, but in stark
ontrast to compulsory detention, these approaches are globally
ffective, represent good value for money and are often cost-saving,
ndicating their value to improving the health outcomes for PWID
nd the broader population.
The internationally endorsed priority harm reduction interven-
ions are fully supported by the available evidence. OST, NSPs and
RT together are effective in reducing drug dependency, reducing
haring of injecting equipment, improving quality of life and avert-
ng HIV infections. Notably, NSPs and OST have been proven to avert
IV cases among PWID, and OST also has greater societal beneﬁts
ssociated with reduction in drug dependency. There is compelling
vidence of value for money for each of the three interventions
cross all regions, with all generally cost-effective in the short-term
nd very cost-effective to cost-saving when long-term and societal
eneﬁts are considered. Importantly, cost-effectiveness ratios in
erms of costs per HIV infection averted among PWID are highly
avorable, ranging from $100 to $1000. Implementing these strate-
ies in combination would likely improve their effectiveness and
ost-effectiveness.
To reverse epidemics of blood-borne viral infections, partic-
larly in a global environment of decreasing HIV/AIDS ﬁnancial
ommitments, and to effectively respond to the social and health
eeds of PWID, it is important to identify the most cost-effective
nterventions. National governments may  wish to re-examine their
pproaches to responding to PWID and consider how the strong
vidence and rationale for harm reduction programs can inﬂuence
uture funding allocations within national public health programs.
lthough the overall costs of scaling up harm reduction programs
ill be high, it will be a worthwhile action for governments to
dopt; not only do the societal beneﬁts of harm reduction pro-
rams exceed treatment costs, but they will also present signiﬁcant
eturns on investment due to infections and subsequent health
osts which are averted. At the same time, governments need to of Drug Policy 26 (2015) S5–S11 S9
ensure sufﬁcient health systems and public sector capacity is in
place to successfully implement harm reduction strategies. This
means investing not only in the strategies themselves but also
investing in health systems infrastructure and overcoming or dis-
mantling structural barriers of access for PWID to health care
services.
The contents and conclusions of the paper reﬂect a broad
consensus among social and clinical scientists participating in
a UNODC Scientiﬁc Consultation on HIV/AIDS (UNODC Scientiﬁc
Consultation, 2014).
Conclusion statements
- There is evidence that opioid-substitution therapy (OST),
needle-syringe programs (NSP) and antiretroviral therapy
(ART) together have established effectiveness in reducing
drug dependency, reducing sharing of injecting equipment,
improving quality of life and averting HIV infections.
- The unit costs of harm reduction interventions are relatively
low, but can vary by provider type, delivery model and region.
Generally, NSPs are least expensive, while the costs of ART
are expected to decline by 2020. OST is a structural inter-
vention with other societal beneﬁts: when such beneﬁts are
included, the attributable cost for HIV budgets and cost-
effectiveness ratios are highly favourable.
- Globally, harm reduction interventions are good value for
money, improving health outcomes for PWID. There is
compelling evidence of cost-effectiveness for each of the
three interventions across all regions. The estimated cost-
effectiveness ratios for priority intervention packages for
PWID and HIV-positive PWID are highly favorable for all
regions, with costs per HIV infection averted ranging from
$100 to $1000.
- The coverage of harm reduction programs is currently too
low across almost all regions. Although the overall costs of
scaling up harm reduction programs will be high, it will a
worthwhile action; not only do the societal beneﬁts of harm
reduction programs exceed treatment costs, but they also
have the potential to provide signiﬁcant returns on invest-
ment for governments.
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